Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen

By Garattini Livio  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 171-171

Springer Publishing Company

Access to resources Recommend Favorite

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

By Cohen Joshua  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 169-170

Springer Publishing Company

Access to resources Recommend Favorite

Major toxicities of carbon nanotubes induced by reactive oxygen species: should we worry about the effects on the lungs, liver and normal cells?

By Muthu Madaswamy S   Abdulla Allabakshi   Pandey Bajarangprasad L  

Nanomedicine, Vol. 8, Iss. 6, 2013-06 ,pp. : 863-866

Future Medicine

Access to resources Recommend Favorite

What we worry about when we worry about the ethics of clinical research

By Wendler David  

Theoretical Medicine, Vol. 32, Iss. 3, 2011-06 ,pp. : 161-180

Springer Publishing Company

Access to resources Recommend Favorite

Which drugs should we be testing for bioavailability [editorial]?

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 2, Iss. 1, 1975-02 ,pp. : 5-7

John Wiley & Sons Inc

Access to resources Recommend Favorite